Ultrasome™ Demonstrates Strong Clinical Signal While Leveraging GMP-Produced CELZ-201 (Olastrocel) to Target Large, Underserved Osteoarthritis Market

PHOENIX, April 28, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced breakthrough positive results from its pilot study of Ultrasome™, the Company's proprietary cell-free regenerative therapy for the treatment of osteoarthritis (OA) of the knee.

The study achieved its primary endpoint with an industry-leading 93% of patients demonstrating clinically meaningful improvements in mobility and pain reduction, with the therapy well-tolerated and no serious adverse events reported.

Ultrasome™ is derived from the Company's GMP-manufactured cell therapy product CELZ-201 (Olastrocel), which is currently being evaluated in the Company's FDA-cleared ADAPT clinical trial. This relationship establishes a direct connection between CELZ's clinical-stage biologic platform and its next-generation cell-free regenerative strategy, expanding the potential applications of CELZ-201 into broader, high-volume indications.